Literature DB >> 22796222

Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro.

Qi Fan1, Xuedi Wang, Hanguang Zhang, Chuanwei Li, Junhua Fan, Jing Xu.   

Abstract

Cathepsin S (Cat S) plays an important role in tumor invasion and metastasis by its ability to degrade extracellular matrix (ECM). Our previous study suggested there could be a potential association between Cat S and hepatocellular carcinoma (HCC) metastasis. The present study was designed to determine the role of Cat S in HCC cell growth, invasion and angiogenesis, using RNA interference technology. Small interfering RNA (siRNA) sequences for the Cat S gene were synthesized and transfected into human HCC cell line MHCC97-H. The Cat S gene targeted siRNA-mediated knockdown of Cat S expression, leading to potent suppression of MHCC97-H cell proliferation, invasion and angiogenesis. These data suggest that Cat S might be a potential target for HCC therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796222     DOI: 10.1016/j.bbrc.2012.07.013

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Cathepsin S silencing induces apoptosis of human hepatocellular carcinoma cells.

Authors:  Xuedi Wang; Li Xiong; Guotang Yu; Dongdong Li; Tao Peng; Daqing Luo; Jing Xu
Journal:  Am J Transl Res       Date:  2015-01-19       Impact factor: 4.060

Review 2.  Cathepsins mediate tumor metastasis.

Authors:  Gong-Jun Tan; Zheng-Ke Peng; Jin-Ping Lu; Fa-Qing Tang
Journal:  World J Biol Chem       Date:  2013-11-26

3.  Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma.

Authors:  Zhi Zhang; Hanguang Zhang; Tao Peng; Dongdong Li; Jing Xu
Journal:  Oncol Lett       Date:  2015-11-23       Impact factor: 2.967

4.  Cathepsin-S degraded decorin are elevated in fibrotic lung disorders - development and biological validation of a new serum biomarker.

Authors:  S N Kehlet; C L Bager; N Willumsen; B Dasgupta; C Brodmerkel; M Curran; S Brix; D J Leeming; M A Karsdal
Journal:  BMC Pulm Med       Date:  2017-08-09       Impact factor: 3.317

5.  Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non-Small Cell Lung Cancer.

Authors:  Nicholas Willumsen; Cecilie L Bager; Diana J Leeming; Anne-Christine Bay-Jensen; Morten A Karsdal
Journal:  Neoplasia       Date:  2017-03-07       Impact factor: 5.715

6.  Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin-mediated apoptosis through the induction of endoplasmic reticulum stress.

Authors:  Seung Un Seo; Kyoung-Jin Min; Seon Min Woo; Taeg Kyu Kwon
Journal:  Exp Mol Med       Date:  2018-08-17       Impact factor: 8.718

Review 7.  Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery.

Authors:  Natalie Fuchs; Mergim Meta; Detlef Schuppan; Lutz Nuhn; Tanja Schirmeister
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

8.  Downregulation of cellular prion protein inhibited the proliferation and invasion and induced apoptosis of Marek's disease virus-transformed avian T cells.

Authors:  Xuerui Wan; Runxia Yang; Guilin Liu; Manling Zhu; Tianliang Zhang; Lei Liu; Run Wu
Journal:  J Vet Sci       Date:  2016-06-30       Impact factor: 1.672

9.  Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors.

Authors:  Chien-Chang Huang; Cheng-Che Lee; Hsiao-Han Lin; Jang-Yang Chang
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

10.  Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma.

Authors:  Ke-Qi Han; Hui Han; Xue-Qun He; Lei Wang; Xiao-Dong Guo; Xue-Ming Zhang; Jie Chen; Quan-Gang Zhu; Hua Nian; Xiao-Feng Zhai; Ma-Wei Jiang
Journal:  Cancer Med       Date:  2016-09-28       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.